Zilucoplan, now Zilbrysq, approved by FDA for AChR-positive gMG
The FDA has approved once-daily zilucoplan as Zilbrysq for adults with generalized MG who are positive for antibodies targeting AChR.| Myasthenia Gravis News
The FDA has approved once-daily zilucoplan as Zilbrysq for adults with generalized MG who are positive for antibodies targeting AChR.| Myasthenia Gravis News
Lindsey Shapiro is a science writer for Myasthenia Gravis News with a PhD in neuroscience. She covers the latest news and information on a variety of myasthenia gravis topics.| Myasthenia Gravis News
Marisa Wexler is a senior science writer for Myasthenia Gravis News with an MS in cellular and molecular pathology. She covers the latest news and information on a variety of myasthenia gravis topics.| Myasthenia Gravis News
Myasthenia gravis occurs when self-reactive antibodies mistakenly attack the body's immune system, causing muscle weakness and fatigue.| Myasthenia Gravis News
Generalized myasthenia gravis is a chronic autoimmune neuromuscular condition that causes muscle weakness in different parts of the body.| Myasthenia Gravis News
Category archive page for News.| Myasthenia Gravis News
